Salvus Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,133
Closed -$270K 124
2024
Q4
$270K Buy
3,133
+69
+2% +$7.46K 0.17% 103
2024
Q3
$365K Buy
3,064
+198
+7% +$26.4K 0.22% 94
2024
Q2
$409K Buy
2,866
+220
+8% +$29.2K 0.28% 85
2024
Q1
$340K Buy
2,646
+416
+19% +$49.5K 0.23% 87
2023
Q4
$231K Buy
+2,230
New +$221K 0.16% 102

Other funds holding NVO

Salvus Wealth Management's NVO Position: Q1 2025 in Review

Salvus Wealth Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 3,133 shares — an estimated $270K sold.

Salvus Wealth Management first reported a position in NVO in Q4 2023 and held it in 5 quarters. The position peaked at $409K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Salvus Wealth Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Salvus Wealth Management sold 3,133 Novo Nordisk shares in Q1 2025, an estimated $270K.
  • Salvus Wealth Management first reported a position in Novo Nordisk in Q4 2023 and held it in 5 quarters.
  • Salvus Wealth Management's Novo Nordisk position peaked at $409K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Salvus Wealth Management's 13F filing for Q1 2025, filed 10 Apr 2025.